View from Washington

Jill Wechsler is ACT's Washington Correspondent

Articles

Following closely contested election, approval of FDA bills most likely tabled until new year.

Potential drug removal spotlights latest debate over the expedited pathway.

CBER maps modernization plan to handle surge in research and applications. 

The ‘skinny’ user fee reauthorization tables multiple high-profile proposals.

Agency releases a series of new guidances to advance the reliability of patient-focused tools and methods.

Seek pared-down measure in funding bill to avert shutdown.

Agency officials express associated concerns around clinical trial data reliability and quality.

Administration launches national manufacturing initiative, with aim to reduce US reliance on biomedicine from China and other regions.

In countdown to renewal deadline, agency already feeling the effects of still-unclear legislative fate.

Pharma loses battle to block price negotiations, but implementation faces many challenges.